nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—Ziprasidone—ADRA1B—polycystic ovary syndrome	0.0155	0.598	CrCbGaD
Lurasidone—Upset stomach—Metformin—polycystic ovary syndrome	0.0112	0.0699	CcSEcCtD
Lurasidone—Ziprasidone—ADRA1A—polycystic ovary syndrome	0.0105	0.402	CrCbGaD
Lurasidone—HTR2A—urine—polycystic ovary syndrome	0.00784	0.108	CbGeAlD
Lurasidone—CYP3A4—urine—polycystic ovary syndrome	0.00726	0.0999	CbGeAlD
Lurasidone—Lethargy—Metformin—polycystic ovary syndrome	0.00545	0.0339	CcSEcCtD
Lurasidone—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00488	0.0304	CcSEcCtD
Lurasidone—Breast disorder—Metformin—polycystic ovary syndrome	0.00482	0.03	CcSEcCtD
Lurasidone—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00477	0.0297	CcSEcCtD
Lurasidone—Influenza—Metformin—polycystic ovary syndrome	0.00461	0.0287	CcSEcCtD
Lurasidone—Angina pectoris—Metformin—polycystic ovary syndrome	0.0045	0.028	CcSEcCtD
Lurasidone—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.00442	0.0275	CcSEcCtD
Lurasidone—Neutropenia—Metformin—polycystic ovary syndrome	0.00432	0.0269	CcSEcCtD
Lurasidone—Infestation—Metformin—polycystic ovary syndrome	0.00411	0.0256	CcSEcCtD
Lurasidone—Infestation NOS—Metformin—polycystic ovary syndrome	0.00411	0.0256	CcSEcCtD
Lurasidone—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00389	0.0242	CcSEcCtD
Lurasidone—Bradycardia—Metformin—polycystic ovary syndrome	0.00376	0.0234	CcSEcCtD
Lurasidone—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00363	0.0226	CcSEcCtD
Lurasidone—Eye disorder—Metformin—polycystic ovary syndrome	0.00345	0.0215	CcSEcCtD
Lurasidone—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00343	0.0213	CcSEcCtD
Lurasidone—Angiopathy—Metformin—polycystic ovary syndrome	0.00335	0.0209	CcSEcCtD
Lurasidone—Malnutrition—Metformin—polycystic ovary syndrome	0.00322	0.02	CcSEcCtD
Lurasidone—Flatulence—Metformin—polycystic ovary syndrome	0.00317	0.0197	CcSEcCtD
Lurasidone—Muscle spasms—Metformin—polycystic ovary syndrome	0.00309	0.0192	CcSEcCtD
Lurasidone—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.00306	0.0421	CbGeAlD
Lurasidone—Vision blurred—Metformin—polycystic ovary syndrome	0.00303	0.0189	CcSEcCtD
Lurasidone—Tremor—Metformin—polycystic ovary syndrome	0.00301	0.0188	CcSEcCtD
Lurasidone—Malaise—Metformin—polycystic ovary syndrome	0.0029	0.0181	CcSEcCtD
Lurasidone—Syncope—Metformin—polycystic ovary syndrome	0.00288	0.018	CcSEcCtD
Lurasidone—Loss of consciousness—Metformin—polycystic ovary syndrome	0.00283	0.0176	CcSEcCtD
Lurasidone—Hypertension—Metformin—polycystic ovary syndrome	0.00278	0.0173	CcSEcCtD
Lurasidone—Myalgia—Metformin—polycystic ovary syndrome	0.00274	0.017	CcSEcCtD
Lurasidone—ADRA2C—endometrium—polycystic ovary syndrome	0.00273	0.0376	CbGeAlD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.00272	0.0169	CcSEcCtD
Lurasidone—Infection—Metformin—polycystic ovary syndrome	0.00261	0.0162	CcSEcCtD
Lurasidone—Shock—Metformin—polycystic ovary syndrome	0.00258	0.0161	CcSEcCtD
Lurasidone—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00257	0.016	CcSEcCtD
Lurasidone—Skin disorder—Metformin—polycystic ovary syndrome	0.00255	0.0159	CcSEcCtD
Lurasidone—DRD2—pituitary gland—polycystic ovary syndrome	0.00255	0.035	CbGeAlD
Lurasidone—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00254	0.0158	CcSEcCtD
Lurasidone—HTR2A—embryo—polycystic ovary syndrome	0.00254	0.0349	CbGeAlD
Lurasidone—ADRA2C—uterus—polycystic ovary syndrome	0.00252	0.0347	CbGeAlD
Lurasidone—HTR1A—adrenal gland—polycystic ovary syndrome	0.00252	0.0346	CbGeAlD
Lurasidone—ADRA2C—pituitary gland—polycystic ovary syndrome	0.00247	0.034	CbGeAlD
Lurasidone—ADRA2C—adipose tissue—polycystic ovary syndrome	0.00246	0.0339	CbGeAlD
Lurasidone—Hypotension—Metformin—polycystic ovary syndrome	0.00245	0.0153	CcSEcCtD
Lurasidone—HTR7—adrenal gland—polycystic ovary syndrome	0.00241	0.0331	CbGeAlD
Lurasidone—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.00239	0.0149	CcSEcCtD
Lurasidone—Dyspnoea—Metformin—polycystic ovary syndrome	0.00234	0.0146	CcSEcCtD
Lurasidone—Somnolence—Metformin—polycystic ovary syndrome	0.00233	0.0145	CcSEcCtD
Lurasidone—Dyspepsia—Metformin—polycystic ovary syndrome	0.00231	0.0144	CcSEcCtD
Lurasidone—Decreased appetite—Metformin—polycystic ovary syndrome	0.00228	0.0142	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00227	0.0141	CcSEcCtD
Lurasidone—Fatigue—Metformin—polycystic ovary syndrome	0.00226	0.0141	CcSEcCtD
Lurasidone—ADRA2C—adrenal gland—polycystic ovary syndrome	0.00221	0.0304	CbGeAlD
Lurasidone—HTR1A—endocrine gland—polycystic ovary syndrome	0.00218	0.03	CbGeAlD
Lurasidone—ADRA2A—endometrium—polycystic ovary syndrome	0.00218	0.03	CbGeAlD
Lurasidone—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00215	0.0134	CcSEcCtD
Lurasidone—HTR7—endocrine gland—polycystic ovary syndrome	0.00209	0.0287	CbGeAlD
Lurasidone—Abdominal pain—Metformin—polycystic ovary syndrome	0.00207	0.0129	CcSEcCtD
Lurasidone—ADRA2C—female gonad—polycystic ovary syndrome	0.00206	0.0283	CbGeAlD
Lurasidone—ADRA2C—vagina—polycystic ovary syndrome	0.00205	0.0282	CbGeAlD
Lurasidone—ADRA2A—uterus—polycystic ovary syndrome	0.00201	0.0277	CbGeAlD
Lurasidone—ADRA2A—pituitary gland—polycystic ovary syndrome	0.00197	0.0272	CbGeAlD
Lurasidone—DRD2—endocrine gland—polycystic ovary syndrome	0.00197	0.0271	CbGeAlD
Lurasidone—ADRA2A—adipose tissue—polycystic ovary syndrome	0.00197	0.027	CbGeAlD
Lurasidone—Asthenia—Metformin—polycystic ovary syndrome	0.00188	0.0117	CcSEcCtD
Lurasidone—Pruritus—Metformin—polycystic ovary syndrome	0.00186	0.0116	CcSEcCtD
Lurasidone—Diarrhoea—Metformin—polycystic ovary syndrome	0.0018	0.0112	CcSEcCtD
Lurasidone—ADRA2A—adrenal gland—polycystic ovary syndrome	0.00176	0.0243	CbGeAlD
Lurasidone—Dizziness—Metformin—polycystic ovary syndrome	0.00174	0.0108	CcSEcCtD
Lurasidone—HTR2A—pituitary gland—polycystic ovary syndrome	0.00168	0.0231	CbGeAlD
Lurasidone—Vomiting—Metformin—polycystic ovary syndrome	0.00167	0.0104	CcSEcCtD
Lurasidone—Rash—Metformin—polycystic ovary syndrome	0.00165	0.0103	CcSEcCtD
Lurasidone—Dermatitis—Metformin—polycystic ovary syndrome	0.00165	0.0103	CcSEcCtD
Lurasidone—ADRA2A—female gonad—polycystic ovary syndrome	0.00164	0.0226	CbGeAlD
Lurasidone—ADRA2A—vagina—polycystic ovary syndrome	0.00163	0.0225	CbGeAlD
Lurasidone—Nausea—Metformin—polycystic ovary syndrome	0.00156	0.00971	CcSEcCtD
Lurasidone—ADRA2A—endocrine gland—polycystic ovary syndrome	0.00153	0.021	CbGeAlD
Lurasidone—HTR2A—adrenal gland—polycystic ovary syndrome	0.0015	0.0206	CbGeAlD
Lurasidone—HTR2A—vagina—polycystic ovary syndrome	0.00139	0.0191	CbGeAlD
Lurasidone—HTR2A—endocrine gland—polycystic ovary syndrome	0.0013	0.0179	CbGeAlD
Lurasidone—CYP3A4—endocrine gland—polycystic ovary syndrome	0.0012	0.0166	CbGeAlD
Lurasidone—ADRA2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000111	0.00015	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—RRM2—polycystic ovary syndrome	0.000111	0.000149	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—YAP1—polycystic ovary syndrome	0.00011	0.000148	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—LHB—polycystic ovary syndrome	0.00011	0.000148	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.00011	0.000148	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NGFR—polycystic ovary syndrome	0.00011	0.000148	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000109	0.000147	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PRL—polycystic ovary syndrome	0.000109	0.000147	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000108	0.000146	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000108	0.000146	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000108	0.000145	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000107	0.000145	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—INSR—polycystic ovary syndrome	0.000107	0.000145	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000107	0.000144	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—YAP1—polycystic ovary syndrome	0.000107	0.000144	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—IGF1—polycystic ovary syndrome	0.000106	0.000143	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—AKT2—polycystic ovary syndrome	0.000106	0.000143	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000106	0.000143	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000105	0.000142	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000105	0.000142	CbGpPWpGaD
Lurasidone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000105	0.000141	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000105	0.000141	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000104	0.00014	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000104	0.00014	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—INSR—polycystic ovary syndrome	0.000104	0.00014	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000103	0.00014	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000103	0.000139	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SCT—polycystic ovary syndrome	0.000103	0.000139	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NAMPT—polycystic ovary syndrome	0.000103	0.000138	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000102	0.000137	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000102	0.000137	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP11A1—polycystic ovary syndrome	0.000101	0.000137	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—SERPINE1—polycystic ovary syndrome	0.000101	0.000136	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—TH—polycystic ovary syndrome	0.0001	0.000135	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.0001	0.000135	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—YAP1—polycystic ovary syndrome	9.97e-05	0.000135	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PGR—polycystic ovary syndrome	9.92e-05	0.000134	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	9.85e-05	0.000133	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—GAB1—polycystic ovary syndrome	9.83e-05	0.000133	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—YAP1—polycystic ovary syndrome	9.81e-05	0.000132	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	9.81e-05	0.000132	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—SLC2A4—polycystic ovary syndrome	9.76e-05	0.000132	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	9.69e-05	0.000131	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—GAB1—polycystic ovary syndrome	9.68e-05	0.000131	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	9.64e-05	0.00013	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PGR—polycystic ovary syndrome	9.59e-05	0.00013	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	9.56e-05	0.000129	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	9.56e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—GNAS—polycystic ovary syndrome	9.55e-05	0.000129	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	9.51e-05	0.000128	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	9.51e-05	0.000128	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	9.42e-05	0.000127	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	9.41e-05	0.000127	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—INSR—polycystic ovary syndrome	9.4e-05	0.000127	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—INSR—polycystic ovary syndrome	9.25e-05	0.000125	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PLAT—polycystic ovary syndrome	9.22e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—GHRL—polycystic ovary syndrome	9.22e-05	0.000124	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CYP19A1—polycystic ovary syndrome	9.17e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NCOR1—polycystic ovary syndrome	9.1e-05	0.000123	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	8.93e-05	0.000121	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NRG1—polycystic ovary syndrome	8.93e-05	0.000121	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	8.92e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—GHRL—polycystic ovary syndrome	8.92e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PLAT—polycystic ovary syndrome	8.92e-05	0.00012	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	8.88e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	8.8e-05	0.000119	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	8.79e-05	0.000119	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ATF1—polycystic ovary syndrome	8.79e-05	0.000119	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	8.79e-05	0.000119	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PGR—polycystic ovary syndrome	8.71e-05	0.000118	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	8.65e-05	0.000117	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	8.59e-05	0.000116	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.58e-05	0.000116	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PGR—polycystic ovary syndrome	8.57e-05	0.000116	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—VEGFA—polycystic ovary syndrome	8.54e-05	0.000115	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.54e-05	0.000115	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ATF1—polycystic ovary syndrome	8.51e-05	0.000115	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	8.42e-05	0.000114	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	8.3e-05	0.000112	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	8.26e-05	0.000112	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—GNAS—polycystic ovary syndrome	8.19e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—TH—polycystic ovary syndrome	8.15e-05	0.00011	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NGFR—polycystic ovary syndrome	8.12e-05	0.00011	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PLAT—polycystic ovary syndrome	8.09e-05	0.000109	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—GHRL—polycystic ovary syndrome	8.09e-05	0.000109	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—POMC—polycystic ovary syndrome	8.06e-05	0.000109	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PRL—polycystic ovary syndrome	8.04e-05	0.000109	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	8e-05	0.000108	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	7.97e-05	0.000108	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PLAT—polycystic ovary syndrome	7.96e-05	0.000108	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—GHRL—polycystic ovary syndrome	7.96e-05	0.000108	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	7.92e-05	0.000107	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	7.87e-05	0.000106	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	7.85e-05	0.000106	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	7.8e-05	0.000105	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	7.8e-05	0.000105	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—POMC—polycystic ovary syndrome	7.8e-05	0.000105	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	7.79e-05	0.000105	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	7.78e-05	0.000105	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.75e-05	0.000105	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ATF1—polycystic ovary syndrome	7.72e-05	0.000104	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	7.67e-05	0.000104	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IRS2—polycystic ovary syndrome	7.65e-05	0.000103	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.63e-05	0.000103	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ATF1—polycystic ovary syndrome	7.6e-05	0.000103	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	7.56e-05	0.000102	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	7.53e-05	0.000102	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	7.5e-05	0.000101	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	7.49e-05	0.000101	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—LEP—polycystic ovary syndrome	7.48e-05	0.000101	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	7.45e-05	0.000101	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	7.41e-05	0.0001	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	7.39e-05	9.98e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.38e-05	9.97e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	7.37e-05	9.96e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	7.25e-05	9.78e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	7.25e-05	9.78e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	7.21e-05	9.74e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	7.13e-05	9.62e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	7.08e-05	9.56e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—GNAS—polycystic ovary syndrome	7.08e-05	9.55e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	7.06e-05	9.53e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	7.01e-05	9.47e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	6.98e-05	9.42e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	6.97e-05	9.41e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	6.95e-05	9.38e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	6.94e-05	9.37e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	6.91e-05	9.33e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	6.89e-05	9.31e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	6.85e-05	9.24e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.81e-05	9.19e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	6.74e-05	9.1e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.74e-05	9.1e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	6.71e-05	9.06e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.7e-05	9.04e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.7e-05	9.04e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IRS1—polycystic ovary syndrome	6.68e-05	9.01e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	6.65e-05	8.98e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NRG1—polycystic ovary syndrome	6.62e-05	8.93e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.59e-05	8.9e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.52e-05	8.81e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—POMC—polycystic ovary syndrome	6.43e-05	8.68e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	6.43e-05	8.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	6.4e-05	8.64e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—INS—polycystic ovary syndrome	6.39e-05	8.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	6.38e-05	8.61e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	6.34e-05	8.56e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	6.34e-05	8.55e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	6.32e-05	8.53e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	6.21e-05	8.39e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IGF1—polycystic ovary syndrome	6.18e-05	8.35e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT2—polycystic ovary syndrome	6.18e-05	8.34e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	6.13e-05	8.28e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	6.11e-05	8.25e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.09e-05	8.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	6.01e-05	8.11e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	6e-05	8.1e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.92e-05	7.99e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.87e-05	7.93e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.82e-05	7.86e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	5.81e-05	7.84e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	5.72e-05	7.72e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	5.67e-05	7.65e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	5.6e-05	7.56e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.59e-05	7.55e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	5.59e-05	7.55e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	5.56e-05	7.51e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	5.55e-05	7.49e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	5.51e-05	7.44e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	5.48e-05	7.4e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—INS—polycystic ovary syndrome	5.48e-05	7.4e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.46e-05	7.38e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	5.37e-05	7.24e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.3e-05	7.15e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	5.29e-05	7.15e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	5.2e-05	7.02e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	4.98e-05	6.72e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.95e-05	6.68e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	4.9e-05	6.61e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.87e-05	6.58e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	4.87e-05	6.57e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	4.79e-05	6.47e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	4.79e-05	6.46e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	4.76e-05	6.43e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	4.74e-05	6.4e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL6—polycystic ovary syndrome	4.73e-05	6.38e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.72e-05	6.37e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	4.61e-05	6.22e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	4.58e-05	6.19e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	4.58e-05	6.19e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	4.58e-05	6.18e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.55e-05	6.14e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	4.54e-05	6.13e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	4.48e-05	6.05e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	4.45e-05	6.01e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—INS—polycystic ovary syndrome	4.45e-05	6.01e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	4.43e-05	5.99e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	4.43e-05	5.98e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.37e-05	5.9e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	4.36e-05	5.88e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.35e-05	5.87e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	4.34e-05	5.86e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4.31e-05	5.82e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	4.27e-05	5.77e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.21e-05	5.68e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	4.18e-05	5.65e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	4.16e-05	5.62e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	4.12e-05	5.56e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	4.09e-05	5.53e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	4.07e-05	5.5e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.04e-05	5.45e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	4.02e-05	5.43e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	4.02e-05	5.43e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	4.01e-05	5.42e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.96e-05	5.34e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.96e-05	5.34e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.89e-05	5.25e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.82e-05	5.16e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.76e-05	5.08e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	3.74e-05	5.05e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	3.72e-05	5.03e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.6e-05	4.86e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.6e-05	4.86e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.5e-05	4.73e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.47e-05	4.69e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.42e-05	4.62e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	3.39e-05	4.58e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.38e-05	4.56e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	3.17e-05	4.29e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	3.08e-05	4.15e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	3.03e-05	4.09e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.99e-05	4.04e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.9e-05	3.91e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.83e-05	3.83e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—polycystic ovary syndrome	2.79e-05	3.77e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.75e-05	3.72e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.7e-05	3.64e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.63e-05	3.55e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.59e-05	3.49e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.56e-05	3.45e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.39e-05	3.22e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.35e-05	3.18e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	2.07e-05	2.79e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	2e-05	2.7e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.93e-05	2.61e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.91e-05	2.58e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.9e-05	2.56e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	1.82e-05	2.45e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.79e-05	2.41e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.63e-05	2.2e-05	CbGpPWpGaD
